Molecular profile
- Entry type
- Peptide research profile
HMG
HMG (human menopausal gonadotropin, also called menotropins) is a purified mixture of the two pituitary gonadotropins, FSH and LH.
Dosing & scaling, explained
Amounts reported for HMG are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
No source-supported amount ladder is shown
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Clinical context
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for HMG
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| FDA label (Menopur): assisted reproductive technology cycleOvulatory women undergoing IVF after GnRH agonist pituitary suppression | 225 IU starting dose; adjustments of no more than 150 IU; never more than 450 IU per day | Once daily, starting on cycle day 2 or 3 | Subcutaneous, abdomen | Until adequate follicular development, not exceeding 20 days, then HCG is givenNot applicable | DailyMed, National Library of Medicine (Ferring Pharmaceuticals label)2026 |
| The label describes a stepwise, individualized scheme: hold 225 IU for 5 days, then adjust by ultrasound and estradiol monitoring no more often than every 2 days. Each vial contains 75 IU FSH and 75 IU LH activity as a lyophilized powder with its own diluent, and HCG is withheld if monitoring suggests a risk of ovarian hyperstimulation. | |||||
| UK label (Menopur SmPC): hypogonadotropic hypogonadism in menMen with hypogonadotropic hypogonadism; the label notes that primary testicular failure usually does not respond | 75 IU or 150 IU of FSH with the matching 75 IU or 150 IU of LH per injection, after HCG 1,000-2,000 IU | 2-3 times weekly for both HCG and menotrophin | Intramuscular or subcutaneous | At least 3-4 monthsNone described | electronic medicines compendium (emc), Ferring Pharmaceuticals UK2025 |
| The UK summary of product characteristics is the regulator document that covers the male indication: spermatogenesis is first stimulated with HCG 1,000-2,000 IU two to three times a week, then menotrophin is added two or three times weekly and continued for at least 3-4 months. The same document gives the anovulatory-woman regimen of 75-150 IU daily for at least 7 days with a 225 IU daily ceiling. | |||||
| Randomized open-label study of HCG alone versus HCG plus HMG51 men with hypogonadotropic hypogonadism at a single endocrine center in Basrah, Iraq | HMG 75 IU per injection, with recombinant HCG 6,500 IU per week split into three doses | HMG 3 times weekly | HMG intramuscular; HCG subcutaneous | Followed through the study period, with the sequential group adding HMG after 6 months of HCG aloneNot applicable | Cureus (PubMed Central)2023 |
| Sperm appeared in the ejaculate in 4 men on HCG alone, 4 on the combination from the start and 7 in the sequential group, a difference that was not statistically significant. The paper reports that prior testosterone exposure did not affect the result, consistent with a 2014 meta-analysis of 44 gonadotropin studies that found a 75% overall success rate for inducing spermatogenesis and better results when HCG and an FSH preparation were combined. | |||||
| Case-based review of hypogonadotropic hypogonadism treatmentMen with hypogonadotropic hypogonadism, including men recovering from anabolic steroid use | HMG 75 IU; HCG 125-500 IU; clomiphene 25 mg | HMG 3 times a week; HCG every other day; clomiphene every other day | HMG and HCG by intramuscular injection; clomiphene oral | Not fixed; the review notes HCG alone maintained sperm production for up to 2 years in a small seriesNot applicable | World Journal of Nephrology (PubMed Central)2015 |
| The review positions HMG as the add-on for men who do not respond to HCG alone, at 75 IU per injection, and lists gynecomastia, dizziness, headache and irregular heartbeat among reported side effects of the gonadotropins. It is an expert summary built from case scenarios and small series rather than a trial. | |||||
| Community-reported1 row | |||||
| Research-vendor listing (format only) | 75 IU per vial | Not stated | Not stated; sold for laboratory research only | Not statedNot stated | Community resource2026 |
| This is a vendor page, not a protocol. It describes a 75 IU pharma-grade vial with a third-party certificate covering identity, endotoxin and a fentanyl screen, and gives no dosing information. The literature it lists on the page is unrelated to gonadotropins, which is worth knowing when weighing the page as a source. | |||||
How a course is commonly described
- Months 1-3 (HCG alone)Clinical
European labeling starts men on HCG 1,000-2,000 IU two to three times a week until there is evidence of adequate testosterone effect, before any HMG is added.
- Months 4 onward (HMG added)Clinical
Menotrophin 75 or 150 IU is then given two or three times weekly alongside the HCG, and the label says to continue for at least 3-4 months because sperm production takes months to appear.
- Clinical comparisonClinical
In the 2023 randomized study, men who started with HCG alone and had HMG 75 IU three times weekly added after 6 months did at least as well as men given both from the start, with sperm appearing in 7 of the sequential group versus 4 in each of the other arms.
- HMG is dosed in international units of FSH and LH activity. A 75 IU vial means 75 IU of each; there is no milligram equivalent.
- In men, HMG is an add-on to HCG, not a stand-alone therapy, and every regimen above runs for months because a cycle of sperm production takes roughly that long.
- Menopur is a prescription product approved in the United States only for women in assisted reproduction. The male regimens come from European labeling and small studies, and research-vendor vials are not FDA approved. The rows above record what sources report, not endorsements of use.
Sources for this section (6)
- Menopur (menotropins for injection) prescribing information
- Menopur 75 IU powder and solvent for solution for injection, Summary of Product Characteristics
- Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins
- Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study
- Treatment of hypogonadotropic male hypogonadism: Case-based scenarios
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
Overview
HMG (human menopausal gonadotropin, also called menotropins) is a purified mixture of the two pituitary gonadotropins, FSH and LH, extracted from the urine of postmenopausal women and standardized so that each vial carries 75 IU of FSH activity and 75 IU of LH activity. In the United States the brand Menopur is approved to grow multiple follicles in women undergoing assisted reproduction, while European labeling also covers its use with HCG to start sperm production in men with hypogonadotropic hypogonadism. It is a mixture of glycoprotein hormones with no single structure, so PubChem has no compound record for it and no chemistry card is shown; every dose is an international unit of activity, never a milligram.
What researchers are exploring
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
- 1
Endocrine & reproductive
Hormonal, reproductive and sexual-function research.
- 2
FDA label (Menopur): assisted reproductive technology cycle
The label describes a stepwise, individualized scheme: hold 225 IU for 5 days, then adjust by ultrasound and estradiol monitoring no more often than every 2 days. Each vial contains 75 IU FSH and 75 IU LH activity as a.
- 3
UK label (Menopur SmPC): hypogonadotropic hypogonadism in men
The UK summary of product characteristics is the regulator document that covers the male indication: spermatogenesis is first stimulated with HCG 1,000-2,000 IU two to three times a week, then menotrophin is added two.
- 4
Randomized open-label study of HCG alone versus HCG plus HMG
Sperm appeared in the ejaculate in 4 men on HCG alone, 4 on the combination from the start and 7 in the sequential group, a difference that was not statistically significant. The paper reports that prior testosterone.
- 5
Case-based review of hypogonadotropic hypogonadism treatment
The review positions HMG as the add-on for men who do not respond to HCG alone, at 75 IU per injection, and lists gynecomastia, dizziness, headache and irregular heartbeat among reported side effects of the.
- 6
Research-vendor listing (format only)
This is a vendor page, not a protocol. It describes a 75 IU pharma-grade vial with a third-party certificate covering identity, endotoxin and a fentanyl screen, and gives no dosing information. The literature it lists.
What the current evidence can support
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
- Human
Human studies and registrations
4 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
- Not graded
Community-reported use
1 row record what blogs, vendor write-ups or forums describe for HMG. None has been verified against primary literature.
Identity, limitations and unknowns
Important limitations
- Every amount on this page is a report of what a source describes, not a protocol to follow.
- Preclinical and community rows do not establish a human amount, schedule or route.
- Formulation, purity and presentation vary by supplier and are not covered by the dossier.
Sources
5 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.
- Menopur (menotropins for injection) prescribing information
- Menopur 75 IU powder and solvent for solution for injection, Summary of Product Characteristics
- Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins
- Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study
- Treatment of hypogonadotropic male hypogonadism: Case-based scenarios